Anixa to Present Positive Phase 1 Lira-cel Survival Data at ISCT Meeting
Anixa Biosciences will present Phase 1 lira-cel ovarian cancer CAR-T positive survival data at International Society for Cell and Gene Therapy Meeting May 6–9 in Dublin. The ongoing trial NCT05316129 is enrolling women with recurrent ovarian cancer after two prior therapies and shows promising survival outcomes.
1. Conference Presentation
Anixa will present Phase 1 lira-cel data at the International Society for Cell and Gene Therapy Meeting in Dublin May 6–9, 2026. Cheryl Cox of Moffitt Cancer Center will discuss trial design, objectives, and survival outcomes from the ongoing study targeting FSHR in recurrent ovarian cancer.
2. Phase 1 Trial Status
The trial NCT05316129 is evaluating autologous T cells engineered to target follicle-stimulating hormone receptor in adult women with recurrent ovarian cancer who progressed after at least two prior therapies. Enrollment is ongoing and interim data continue to show positive survival benefit without significant off-target toxicity.
3. Lira-cel CAR-T Therapy Mechanism
Liraltagene autoleucel uses a chimeric endocrine receptor-T cell approach that employs the natural FSH ligand to bind FSHR on tumor vasculature and ovarian cancer cells. This targeted mechanism distinguishes lira-cel from antibody-based CAR-T therapies and may reduce effects on healthy tissue.
4. Potential Investor Impact
Positive survival data in an early-stage trial could enhance Anixa’s valuation as it advances toward regulatory milestones and potential partnerships. Upcoming full data release at ISCT may drive renewed investor interest and impact Anixa’s clinical-stage pipeline perception.